Xenon Pharmaceuticals/$XENE
1D1W1MYTD1Y5YMAX
Capital at risk
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
- Ticker
- $XENE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 364
- Headquarters
- Burnaby, Canada
- Website
- www.xenon-pharma.com
XENE Metrics
BasicAdvanced
$5.5B
-
-$4.73
0.63
-
Price and volume
Market cap
$5.5B
Beta
0.63
52-week high
$72.66
52-week low
$35.66
Average daily volume
632K
Financial strength
Current ratio
21.015
Quick ratio
20.678
Long term debt to equity
0.004
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-439.189
Effective tax rate (TTM)
0.47%
Management effectiveness
Return on assets (TTM)
-28.02%
Return on equity (TTM)
-43.62%
Valuation
Price to book
4.38
Price to tangible book (TTM)
4.38
Price to free cash flow (TTM)
-14.394
Free cash flow yield (TTM)
-6.95%
Free cash flow per share (TTM)
-3.91
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
33.32%
3-year earnings per share growth (CAGR)
23.78%
10-year earnings per share growth (CAGR)
14.77%
What the Analysts think about XENE
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
Analyst projections of the future price of Xenon Pharmaceuticals stock.
XENE Financial Performance
Revenues and expenses
XENE Earnings Performance
Company profitability
Upcoming events
No upcoming events
XENE News
AllArticlesVideos
Funds containing XENE
AllUSDEURGBP
Fund name | Fund size | $XENE weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.59% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.59% |
iShares Healthcare Innovation£DRDR | £1B | 0.59% |
iShares Ageing Population€AGED | €822M | 0.48% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.38% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.